Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB1 in Adult Patients With Sickle Cell Disease
NCT05261711Phase 2Terminated
- Sponsor
- AkiraBio
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AB1 in sickle cell disease (SCD), sponsored by AkiraBio. Primary endpoints: Total Number of Adverse Events/Serious Adverse Events at 12 months and Number of Participants With >=Grade 2 Study Related Adverse Events at 12 months. Started Dec 2022; status: terminated.
02
Drugs
AB1
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05261711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261711.